Insilico Medicine to present at the XPOMET Medicinale Festival 2019
Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, to present at the XPOMET Medicinale Festival 2019 in Berlin on October 10th
Credit: Insilico Medicine
Wednesday, July 24 – Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at XPOMET © Medicinale in Berlin on October 10.
XPOMET © Medicinale is the three-day technology and medicine festival which inspires and guides all responsible persons from the healthcare industry, the life science industry and health foundations. The festivals covers the new worlds of robotics, artificial intelligence, precision medicine, regenerative medicine, nanomedicine, wearables, Internet-of-Things for Healthcare, 3D printing and the latest start-up innovations. Over 5,000 guests from across Europe and around the world will see 150 inspiring speakers, 15 workshops and think tanks and more than 200 of the most innovative companies discover and promote new transdisciplinary solutions, business models and partnerships in medicine and life sciences.
Use this promo code to get an early ticket and a discount at XPOMET 2019: XpometZhavoronkov
“At XPOMET©, we aim to create a platform connecting important stakeholders in the next generation healthcare and focus on ecosystem based healthcare problems improving accessibility. As a part of this vision, we are organizing XPOMET© Medicinale© a next generation healthcare festival bringing together world’s leading players and decision makers in the next generation healthcare. Our focus is to sustain communities beyond the concept of events and create value from these communities,” said Dr. Jubin Shah, Conference Head at XPOMET©.
“We are happy to present our latest research at the XPOMET Festival, which gathers the key scientists of the ageing research. The topic of AI for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
For further information, images or interviews, please contact:
Contact: Klug Gehilfe [email protected]
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/